Story

Clariant Upgraded by Goldman Sachs, Berenberg on Reduced Litigation Risk

ENTHMSVIIDZHZH-TWJAKOHI
Aug 12, 20262 min read
Clariant Upgraded by Goldman Sachs, Berenberg on Reduced Litigation Risk
Text size
Background

Swiss specialty chemicals firm Clariant AG (CLN) received upgraded ratings from both Berenberg and Goldman Sachs, who now rate the stock a “Buy” from “Hold.” In separate notes, the analysts cited a significant reduction in litigation risk following a favorable court ruling and an expected recovery in the company's underperforming Catalysts division.

Favorable Ruling Eases Litigation Overhang

A key driver for the upgrades was a late July decision by the Amsterdam District Court, which dismissed a €1 billion damages claim from Shell Chemicals Europe. The claim was related to an alleged ethylene cartel, and the court found no plausible impact on the monthly contract reference price for the chemical.

This ruling materially lessens a major risk for Clariant, which faced aggregate potential claims of roughly €10 billion—about four times its market capitalization. Following the decision, Berenberg cut its litigation reserve estimate for Clariant to CHF 200 million from a previous CHF 900 million. Goldman Sachs stated the development allows the market to now "risk-adjust" the potential liability.

Catalyst Division Poised for Rebound

Both investment banks also highlighted the potential for a turnaround in Clariant's Catalysts segment, which has been a primary drag on recent performance. The division's volumes fell 14.2% year-on-year in the second quarter of 2026, a decline management attributed largely to order delays from the Middle East.

Sample IUX Markets – In-articleAd

Goldman Sachs identified the first quarter of 2026 as the trough for the unit, when its adjusted EBITDA margin fell to 9% from 16% a year earlier. The bank now expects a "Catalysts refill cycle to inflect ahead," signaling a positive outlook for future demand.

Analyst Outlook and Valuation

Both Berenberg and Goldman Sachs issued a matching price target of CHF 12 per share. However, their earnings forecasts diverge, reflecting different views on the speed of the recovery. Goldman's fiscal 2027 EBITDA estimate is 5.8% above the Visible Alpha consensus, while Berenberg's is approximately 5% below consensus.

Goldman's sum-of-the-parts analysis suggests a full value of CHF 17.10 per share, but its lower price target reflects the remaining litigation pending in other European courts. Clariant shares closed Tuesday at CHF 10.04 on the SIX Swiss Exchange, near their 52-week high.

Read next

More on Stocks
Back to latest news

LATEST